PLGA-PEG-PLGA from PolySciTech used in development of infantile hemangioma treatment
Infantile hemangioma is a non-cancerous tumor in which
an excess of blood vessels grow in a particular area with excessive cell proliferation.
Small, skin hemangioma’s manifest as
benign birthmarks and do not typically require treatment. However, large
hemangioma’s or hemangioma’s that affect organs (especially the liver) can be
fatal and require treatment. Since these affect primarily infants, treatment
must be performed carefully as side-effects and other complications can be readily
encountered due to size and metabolic features in very small children. Recently,
researchers from Henan Provincial People’s Hospital and Second Military Medical
University utilized PLGA-PEG-PLGA (Polyvivo#: AK016) from PolySciTech (www.polyscitech.com) to formulate
urea-loaded microspheres as a delivery system to treat hemangioma. This
research holds promise for treating this potentially life-threatening infantile
disease. Read more: Zhu, Xiaoshuang, Xiaonan Guo, Dakan Liu, Yubin Gong, Jin
Sun, and Changxian Dong. "Significant inhibition of infantile hemangioma
growth by sustained delivery of urea from liposomes-in-microspheres."
Oncology Reports 39, no. 1 (2018): 109-118. https://www.spandidos-publications.com/or/39/1/109
“Abstract: Infantile
hemangioma (IH) is a benign pediatric tumor, and rapid growth of IH can result
in serious morbidity and even mortality. Only one drug Hemangeol™ (propranolol
hydrochloride oral solution) has been approved for the treatment of IH, whereas
patients suffer from its adverse effects and high frequency of administration.
We have used urea, an organic compound and a normal body metabolite, in the
treatment of IH for 20 years, and demonstrated that urea is an effective and
well-tolerated treatment for IH. To reduce the daily administration of urea, we
firstly utilized urea-loaded liposomes-in-microspheres (ULIM) as a novel
topical controlled release system to realize the sustained release of urea.
ULIM were fabricated from the encapsulation of urea-loaded liposomes in
poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic
acid) microspheres. The characteristics, activity and mechanism against IH of
ULIM were examined in vitro and in vivo. ULIM were of a desired particle size
(~62.4 µm), drug encapsulation efficiency (~51.5%) and sustained drug release
for 40 days. ULIM inhibited the proliferation of hemangioma endothelia cells
(HemECs) and expression of vascular endothelial growth factor-A in HemECs. The
therapeutic effect of ULIM in IH was better than propranolol, urea, urea-loaded
liposomes and urea-loaded microspheres in vivo, as reflected by markedly
decreased hemangioma weight, volume and microvessel density. None of the
treated mice showed behavioral changes, severe side‑effects and weight
loss. Our results suggest that use of ULIM is a potential and safe approach
with which to locally and efficiently deliver urea to hemangioma, and is a
promising alternative to propranolol in the treatment of IH.”
No comments:
Post a Comment